ArticleBMC bioinformatics2011
Statistical methods for analyzing immunosignatures.
Article in BMC bioinformatics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Use of principal components analysis and protein microarray to explore the association of HIV-1-specific IgG responses with disease progression.AIDS research and human retroviruses · 2014Trial
- Highly heterogenous humoral immune response in Lyme disease patients revealed by broad machine learning-assisted antibody binding profiling with random peptide arrays.Frontiers in immunology · 2024Article
- Modeling the sequence dependence of differential antibody binding in the immune response to infectious disease.PLoS computational biology · 2023Article
- Antibody characterization using immunosignatures.PloS one · 2020Article
- High-Density Redox Amplified Coulostatic Discharge-Based Biosensor Array.IEEE journal of solid-state circuits · 2018Article
- Entropy is a Simple Measure of the Antibody Profile and is an Indicator of Health Status: A Proof of Concept.Scientific reports · 2017Article
- Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients.PloS one · 2017Article
- General Assessment of Humoral Activity in Healthy Humans.Molecular & cellular proteomics : MCP · 2016Article
- Time-Frequency Analysis of Peptide Microarray Data: Application to Brain Cancer Immunosignatures.Cancer informatics · 2015Article
- Comparative study of classification algorithms for immunosignaturing data.BMC bioinformatics · 2012Article
- Systems biology in vaccine design.Microbial biotechnology · 2012Review
- A minimal model of peptide binding predicts ensemble properties of serum antibodies.BMC genomics · 2012Article
- Article
- Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunosignaturing is a new peptide microarray based technology for profiling of humoral immune responses. Despite new challenges, immunosignaturing gives us the opportunity to explore new and fundamentally different research questions. In addition to classifying samples based on disease status, the complex patterns and latent factors underlying immunosignatures, which we attempt to model, may have a diverse range of applications.
methodsWe investigate the utility of a number of statistical methods to determine model performance and address challenges inherent in analyzing immunosignatures. Some of these methods include exploratory and confirmatory factor analyses, classical significance testing, structural equation and mixture modeling.
resultsWe demonstrate an ability to classify samples based on disease status and show that immunosignaturing is a very promising technology for screening and presymptomatic screening of disease. In addition, we are able to model complex patterns and latent factors underlying immunosignatures. These latent factors may serve as biomarkers for disease and may play a key role in a bioinformatic method for antibody discovery.
conclusionBased on this research, we lay out an analytic framework illustrating how immunosignatures may be useful as a general method for screening and presymptomatic screening of disease as well as antibody discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.